Saturday 17 October 2026
Export GANX’s income statement to Excel — free account
Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
1.26
0.07
−5.26%
Follow GANX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
— | — | 1 | 3 | 5 | — | — | — | — |
P/S ratio |
— | — | 241.83 | 210.04 | 334.52 | 1,039.00 | 1,039.00 | 1,039.00 | — |
Altman Z-Score |
— | — | (1.79) | 1.48 | 7.61 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | (8.07) | 0.63 | 11.72 | 3.00 | (32.50) | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | — | (2.45) | 4.46 | (3.00) | — | — | — |
P/Operating CF |
— | — | (8.34) | (9.86) | (13.31) | (22.96) | (22.96) | (22.96) | — |
P/B ratio |
— | — | 3.75 | 2.04 | 1.59 | 4.84 | 4.84 | 4.84 | — |
Price to Tangible BV |
— | — | 3.75 | 2.04 | 1.59 | 4.84 | 4.84 | 4.84 | — |
EV/Sales |
— | — | 158.75 | 103.47 | 115.21 | 804.89 | 804.89 | 804.89 | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | (1.64) | (1.29) | (1.54) | (7.18) | (7.18) | (7.18) | — |
EV/FCF |
— | — | (1.64) | (1.28) | (1.53) | (7.13) | (7.13) | (7.13) | — |
Quick Ratio |
6.22 | 2.66 | 3.39 | 4.88 | 14.45 | 3.55 | 0.35 | — | — |
Current Ratio |
6.63 | 2.97 | 3.59 | 5.11 | 14.78 | 4.25 | 0.49 | — | — |
Net Debt/EBITDA |
1.10 | 0.49 | 0.73 | 1.10 | 2.62 | 1.95 | 0.05 | 0.00 | — |
Debt/Assets |
1.76% | 3.62% | 3.05% | 2.50% | 1.78% | 7.69% | 30.43% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.06 | 0.05 | 0.03 | 0.02 | 0.12 | (0.45) | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.13 | 0.00 | — |
Operating CF/Net income |
0.92 | 0.92 | 0.85 | 0.84 | 0.89 | 0.91 | 0.85 | 0.67 | — |
Capex/Depreciation |
0.00 | (0.27) | (0.18) | (1.85) | (6.08) | (2.17) | (5.27) | (11.43) | — |
| (155.66%) | (204.95%) | (141.57%) | (65.52%) | (67.73%) | (124.41%) | (76.27%) | 0.00% | — | |
| (115.39%) | (132.83%) | (104.28%) | (55.77%) | (57.18%) | (69.71%) | (664.36%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(106.34%) | (261.86%) | (171.88%) | (102.81%) | (39.38%) | (51.83%) | 508.67% | 0.00% | — |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 107.35 | 74.24 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 20,870.65% | 5,979.51% | 4,341.94% | 7,817.30% | 3,840.68% | 4,014.08% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 19,542.93% | 6,809.35% | 4,137.52% | 4,322.15% | 1,344.31% | 1,077.67% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 5,903.99% | 1,089.51% | 508.73% | 282.35% | 0.00% | 0.00% | — |
Graham Net Nets |
— | — | 0.25 | 0.41 | 0.61 | 0.19 | 0.19 | 0.19 | — |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | (47.11%) | (45.68%) | (26.52%) | (11.88%) | (11.88%) | (11.88%) | — |
Free Cash Flow Yield |
— | — | (39.98%) | (38.47%) | (22.57%) | (10.86%) | (10.86%) | (10.86%) | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.01 | — |
Operating CF per Share |
(0.56) | (0.82) | (1.45) | (1.24) | (1.22) | (1.21) | (0.83) | (0.33) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | (0.01) | 0.00 | — |
Free Cash Flow per Share |
(0.56) | (0.83) | (1.45) | (1.25) | (1.23) | (1.22) | (0.84) | (0.33) | — |
Cash per Share |
0.63 | 0.45 | 1.29 | 1.69 | 3.63 | 2.80 | 0.13 | 0.00 | — |
Shareholders Equity per Share |
0.56 | 0.32 | 0.97 | 1.59 | 3.43 | 2.31 | (0.20) | 0.00 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.56 | 0.32 | 0.97 | 1.59 | 3.43 | 2.31 | (0.20) | 0.00 | — |
Free Cash Flow |
(18.47) | (18.90) | (18.88) | (14.81) | (12.46) | (3.26) | (1.88) | (0.75) | — |
Working Capital |
18.88 | 7.69 | 12.83 | 16.97 | 35.17 | 6.87 | (0.45) | — | — |
Capital Expenditures |
— | (0.02) | (0.02) | (0.12) | (0.09) | (0.02) | (0.01) | (0.01) | — |
Net Current Asset Value |
17.98 | 6.82 | 11.75 | 15.87 | 33.55 | 5.59 | (0.68) | 0.00 | — |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
— | 0.00 | 0.28 | 0.85 | 0.57 | 0.72 | 0.33 | 0.39 | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.26 | 0.81 | 0.66 | 0.44 | 0.15 | 0.32 | 0.14 | 0.00 | — |
Cash ROIC |
(46.39%) | (104.03%) | (63.06%) | (37.38%) | (17.21%) | (22.58%) | (3,466.30%) | 0.00% | — |
Accounts Receivable Turnover |
— | — | 0.00 | 0.72 | 1.62 | 3.42 | 0.74 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | — |
Average Receivables |
— | — | — | 0.19 | 0.10 | 0.01 | 0.06 | — | — |
Average Payables |
0.89 | 1.13 | 1.47 | 1.09 | 0.76 | 0.56 | 0.56 | — | — |
Average Assets |
17.47 | 15.37 | 21.35 | 31.54 | 24.29 | 5.13 | 0.33 | 0.00 | — |
Average Common Equity |
12.95 | 9.96 | 15.73 | 26.85 | 20.51 | 2.88 | 2.88 | — | — |
Columns are period end dates